CancerNCT03139188
Palliative Care Unit Transfert Announcements
An observational study of Cancer, run by University Hospital, Strasbourg, France at 2 sites in France.
Trial summary
The course of care of a patient with a cancer whose evolution is pejorative, is marked by difficult announcements, called "bad news". In the palliative phase, prognostic announcements are at the forefront. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- How many people
- 10 participants
- Where
- 2 sitesFrance
- Study dates
- 2 May 2017to Apr 2018
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients over 18 years old with solid cancer or malignant haemopathy in palliative phase transferred from a HUS service to the HUS UnASP
Who may be able to join
- Patients over 18 years old with solid cancer or malignant haemopathy in palliative phase transferred from a HUS service to the HUS UnASP and informed of this transfer by the originating doctor .
- HUS senior hospital doctors, supporting patients with solid cancers or malignant hemopathies.
Who cannot join
- Patients whose clinical state does not allow for maintenance (tiredness, confusion) or difficult communication.
Trial locations and contacts
2 sites in 1 country.
France2 sites, 2 recruiting
- Not yet recruiting
Service : Unité de soins d'Accompagnement de soins de Support et de soins Palliatifs (UnASP)
Strasbourg, 67091
Virginie LEROY, MD, 03 88 11 65 84, virginie.leroy@chru-strasbourg.fr
Laurent CALVEL, MD, PhD, 33 3 88 11 52 66, laurent.calvel@chru-strasbourg.fr
- Recruiting
Service : Unité de soins d'Accompagnement de soins de Support et de soins Palliatifs (UnASP)
Strasbourg, 67091
Virginie Leroy, MD, 03 88 11 65 84, virginie.leroy@chru-strasbourg.fr
Laurent CALVEL, MD, PhD, 03 88 11 52 66, laurent.calvel@chru-strasbourg.fr
About this study
Official title: Palliative Care Transfer Announcements: Qualitative Analysis of the Perspective of Physicians and Their Patients With Cancer
The course of care of a patient with a cancer whose evolution is pejorative, is marked by difficult announcements, called "bad news". In the palliative phase, prognostic announcements are at the forefront. Of these, the announcement of a transfer to the Palliative Care Unit has not been the subject of any specific studies to the best of our knowledge. It therefore seemed interesting to us to explore the stakes of this particular announcement, a source of upheaval for the doctor and the patient, by gathering the point of view of each one.
The objective of our study is to analyze the methods of announcing a transfer to the Palliative Care Unit and the perception of this announcement by the doctor and his patient with an incurable cancer.
- Conditions
- Cancer
- Keywords
- Cancer, incurable pathologies, palliative care
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Analysis of semi-structured interviews exploring how the physician analyzes and feels the announcement of the transfer to the Palliative Care Unit and how the patient receives and disseminates this information
Measured: 72 hours after the transfer of the patient the to the Palliative Care Unit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2017
- Study start2 May 2017
- Primary completionApr 2018 (estimated)
- Study completionApr 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Virginie LEROY, MD, Study director, University Hospital, Strasbourg, FranceLaurent CALVEL, MD, PhD, Principal investigator, University Hospital, Strasbourg, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03139188
- Sponsor's protocol ID
- 6789
- Status last verified
- May 2017
- First submitted
- 21 Apr 2017
- Last updated
- 23 May 2017
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Palliative Care Transfer Announcements: Qualitative Analysis of the Perspective of Physicians and Their Patients With Cancer
- ClinicalTrials.gov ID
- NCT03139188
- Acronym / sponsor ID
- 6789
- Conditions
- Cancer
- Keywords
- Cancer, incurable pathologies, palliative care
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 2 May 2017 (actual)
- Primary completion
- Apr 2018 (estimated)
- Study completion
- Apr 2018 (estimated)
- First posted
- 3 May 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The course of care of a patient with a cancer whose evolution is pejorative, is marked by difficult announcements, called "bad news". In the palliative phase, prognostic announcements are at the forefront. Of these, the announcement of a transfer to the Palliative Care Unit has not been the subject of any specific studies to the best of our knowledge. It therefore seemed interesting to us to explore the stakes of this particular announcement, a source of upheaval for the doctor and the patient, by gathering the point of view of each one.
The objective of our study is to analyze the methods of announcing a transfer to the Palliative Care Unit and the perception of this announcement by the doctor and his patient with an incurable cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients over 18 years old with solid cancer or malignant haemopathy in palliative phase transferred from a HUS service to the HUS UnASP
Key inclusion criteria (2 listed)
- Patients over 18 years old with solid cancer or malignant haemopathy in palliative phase transferred from a HUS service to the HUS UnASP and informed of this transfer by the originating doctor .
- HUS senior hospital doctors, supporting patients with solid cancers or malignant hemopathies.
Key exclusion criteria (1 listed)
- Patients whose clinical state does not allow for maintenance (tiredness, confusion) or difficult communication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Analysis of semi-structured interviews exploring how the physician analyzes and feels the announcement of the transfer to the Palliative Care Unit and how the patient receives and disseminates this information
Time frame: 72 hours after the transfer of the patient the to the Palliative Care Unit
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2017.
- Individual participant dataSharing planned: No
Related trials for Cancer
RecruitingPhase 1
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors
Solid Tumor
RecruitingPhase 1
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Virginie LEROY, MD study director
University Hospital, Strasbourg, France
Laurent CALVEL, MD, PhD principal investigator
University Hospital, Strasbourg, France
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by University Hospital, Strasbourg, France at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Virginie LEROY, MD (03 88 11 65 84, virginie.leroy@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analysis of semi-structured interviews exploring how the physician analyzes and feels the announcement of the transfer to the Palliative Care Unit and how the patient receives and disseminates this information (time frame: 72 hours after the transfer of the patient the to the Palliative Care Unit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2017.